22nd Century Group to Sell GVB Biopharma to Nevada Consortium
According to a report from Newsfile Corp on December 14, the American biotechnology company 22nd Century Group, Inc announced that it has obtained approval from its original creditor bank to sell its GVB Biopharma cannabis/narcotics business to a Nevada consortium affiliated with GVB employees (Specialty Acquisition Corporation). This transaction is expected to help 22nd Century Group reduce its existing debt of $5.2 billion.
Larry Firestone, Chairman and CEO of 22nd Century Group, stated, "We are pleased to further reduce debt in the process of obtaining approval from the bank. This represents significant progress in repaying the principal of our credit facilities by the third quarter of 2024.
As previously announced, the insurance funds from the fire incident at the company's Grass Valley manufacturing facility are expected to be used for further debt reduction. Currently, the company is claiming approximately $9 million, although the final amount received will depend on the resolution of the matter.
The transaction is expected to be formally completed in December 2023, subject to the usual closing conditions.
The 22nd Century Group, Inc. is an agricultural biotechnology company that focuses on harm reduction in tobacco, low nicotine tobacco, and improving health and well-being through plant technology.
Notice
1. This article is provided exclusively for professional research purposes related to industry, technology and policy. Any reference to brands or products is made solely for the purpose of objective description and does not constitute an endorsement, recommendation, or promotion of any brand or product.
2. The use of nicotine products, including but not limited to cigarettes, e-cigarettes, and heated tobacco products, is associated with significant health risks. Users are required to comply with all relevant laws and regulations in their respective jurisdictions.
3. This article is strictly restricted from being accessed or viewed by individuals under the legal age.
Copyright
This article is either an original work by 2Firsts or a reproduction from third-party sources with the original source clearly indicated. The copyright and usage rights of this article belong to 2Firsts or the original source. Unauthorized reproduction, distribution, or any other unauthorized use of this article by any entity or individual is strictly prohibited. Violators will be held legally responsible. For copyright-related matters, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have utilized AI to enhance translation and editing efficiency. However, due to technical limitations, errors may occur. Readers are advised to refer to the sources provided for more accurate information.
This article should not be used as a basis for any investment decisions or advice, and 2Firsts assumes no direct or indirect liability for any errors in the content.
